TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41061

Peptide_Name

ZXR-1

Activity

Anticancer Cell-penetrating Peptides

Activity_category_statistics

Cancer-related peptides Delivery and barrier-penetrating peptides

Database_Source

CancerPPD 2.0 dbACP CPPsite3.0

Sequence_Type

standard

Has_Modification No

Description A 16-aa standard natural multi-activity (Anticancer and Cell-penetrating Peptides) peptide sequence curated from CancerPPD 2.0, dbACP, and CPPsite3.0, with an available 3D structural model.

Sequence

FKIGGFIKKLWRSKLA

FASTA

>TPDB41061|Anticancer;Cell-penetrating Peptides|length=16
FKIGGFIKKLWRSKLA

Formula C93H150N24O18

Absent Amino Acids NDCEQHMPTYV

Common Amino Acids K

Mass 1892.36

PI 11.80

Basic Residues 5

Acidic Residues 0

Hydrophobic Residues 8

Net Charge +5

Boman Index -1.10

Hydrophobicity 0.087

Aliphatic Index 103.75

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 5500

Absorbance 280nm 290.64

Polar Residues 1

number

1

A

1

R

0

N

0

D

0

C

0

E

0

Q

2

G

0

H

2

I

2

L

4

K

0

M

2

F

0

P

1

S

0

T

1

W

0

Y

0

V

Amino Acid Distribution

A: 1 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 2 L: 2 K: 4 M: 0 F: 2 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 0

Length

16

Formula

C93H150N24O18

Mass

1892.36

PI

11.80

Net Charge

+5

Boman Index

-1.10

Hydrophobicity

0.087

C_terminal_Modification

Free

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Mauriporin

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 62.6 ± 8.4 µM

Detail Source Activity Anticancer

Activity Measurement 62.6

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT assay

Testing Time 4-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2016

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 27.9 ± 7.7 µM

Detail Source Activity Anticancer

Activity Measurement 27.9

Target

Cancer Type Salivary Cancer

Cell Line SACC-83

Tissue Affected Salivary gland

Assay & Model

Assay MTT assay

Testing Time 4-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2016

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 141.7 ± 12.2 µM

Detail Source Activity Anticancer

Activity Measurement 141.7

Target

Cancer Type Liver Cancer

Cell Line HepG-2

Tissue Affected Liver

Assay & Model

Assay MTT assay

Testing Time 4-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2016

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 77.9 ± 0.9 µM

Detail Source Activity Anticancer

Activity Measurement 77.9

Target

Cancer Type Liver Cancer

Cell Line Huh-7

Tissue Affected Liver

Assay & Model

Assay MTT assay

Testing Time 4-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2016

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 69.1 ± 1.6 µM

Detail Source Activity Anticancer

Activity Measurement 69.1

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT assay

Testing Time 4-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2016

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 186.7 ± 13.1 µM

Detail Source Activity Anticancer

Activity Measurement 186.7

Target

Cancer Type Kidney Cancer

Cell Line 293T

Tissue Affected Kidney

Assay & Model

Assay MTT assay

Testing Time 4-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2016